Yunlan Ding

机构：Shanghai Medical College of Fudan University, Fudan University Shanghai Cancer Center

发表论文 7 篇 · 总被引 50 次 · h-index 2

代表论文

• Safety of trastuzumab deruxtecan: A meta‐analysis and pharmacovigilance study (2022 · Journal of Clinical Pharmacy and Therapeutics · 被引 36)
• Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study (2024 · Pharmaceuticals · 被引 10)
• Unveiling the hidden risks of nanomedicine-based drug delivery: a comparative evaluation of drug safety profiles of liposomal irinotecan and conventional irinotecan (2026 · Nanotoxicology · 被引 2)
• Pharmacovigilance insights into drug-induced hypercalcemia: evidence from the U.S. FDA Adverse Event Reporting System (FAERS) database (2026 · Naunyn-Schmiedeberg s Archives of Pharmacology)
• Characteristics of adverse events of liposomal irinotecan: a real-world study based on the FAERS database (2026 · DOAJ (DOAJ: Directory of Open Access Journals))
• Unveiling the hidden risks of nanomedicine-based drug delivery: a comparative evaluation of drug safety profiles of liposomal irinotecan and conventional irinotecan (2026 · Open MIND)